INTRODUCTION
DRUG DISSOLUTION PROCESS
DISSOLUTION PROFILES COMPARISON
DISSOLUTION MODELS/METHODS TO COMPARE DISSOLUTION PROFILE WITH PROPER CLASSIFICATION & EXPLANATIONS
CONCLUSION
It is a graphical represents in terms of (Concentration Vs Time) of complete release of API from a dosages form in a appropriate selected dissolution medium, i.e., in short it is the measure of the release of API form a dosage from with respect to time
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Β
Modelling & comparison of dissolution profiles by Paulo Costa
1. MODELLING & COMPARISON OF
DISSOLUTION PROFILES
BY MAHENDRA PRATAP SWAIN
Regd. No.: PHDPH100102019
BIRLA INSTITUTE OF TECHNOLOGY, MESRA, RANCHI
2. CONTENT IN
β’ INTRODUCTION
β’ DRUG DISSOLUTION PROCESS
β’ DISSOLUTION PROFILES COMPARISON
β’ DISSOLUTION MODELS/METHODS TO COMPARE DISSOLUTION PROFILE WITH
PROPER CLASSIFICATION & EXPLANATIONS
β’ CONCLUSION
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
2
3. INTRODUCTION
β’ DEFINITION:
β’ It is a graphical represents in terms of (Concentration Vs Time) of complete release of
API from a dosages form in a appropriate selected dissolution medium, i.e., in short it
is the measure of the release of API form a dosage from with respect to time
β’ Rate of dissolution:
Amount of drug substance that goes in the solution per unit time under standardise
condition of liquid pH, solvent, temperature.
By kinetic model, dissolved amount of drug (Q) is a function of test time βtβ
π = π(π‘)
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
3
4. INTRODUCTION (CONT..)
β’ The kind of drug, its polymorphic form, crystallinity, particle size, solubility &
amount in the pharmaceutical dosage form can influence the release kinetics
(Salomon & Doelker, 1980; El-Arini & Leuenberger, 1995)
β’ A water soluble Drug = in Matrix = By Diffusion
β’ Low Water soluble Drug = in Matrix = Self Erosion of Matrix
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
4
5. DRUG DISSOLUTION PROCESS
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
5
Tablet Granules Small Particles
Drug in
Solution
Very
Limited
Dissolution
Limited
Dissolution
Best
Dissolution
Disintegration Disintegration
6. WHY DISSOLUTION STUDY..??
β’ OBJECTIVES:
β’ To study the release of drug in desired amount from dosage form.
β’ To study the uniformity of drug release from dosage form of different batches.
β’ To show that drug release is equivalent to those batches proven to be bioavailable and
clinically effective.
β’ To demonstrating equivalence after change in formulation of the Drug Product or
preparation of Pharmaceutically equivalent product
β’ To Development a Bioequivalent product
β’ To optimize dosage formula by comparing the dissolution profile of various formulas of
same API or to get chemically equivalent products.
β’ To achieve desired dissolution profile w.r.t. condition & time in IR, MR formulations
β’ To develop IVIV correlation which help to reduce Cost, Speed Up Product development &
reduce need of preform costly bioavailability human volunteer studies
β’ To stabilize final dissolution specification for Regulatory filling
β’ To Dissolution profiles od SUPAC (Scale-Up-Post-Approval-Changes) Product.
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
6
7. DISSOLUTION MODELS/METHODS :
A. GRAPHICAL METHOD
B. STATISTICAL METHOD
a. t-studentβs Test
I. Single Time
II. Multiple time Point
b. ANOVA
c. MANOVA
C. MATHEMATICAL MODELS DEPENDANTS
METHOD
a. Zero Order Kinetics Model
b. First Order Kinetics Model
c. Weibull Model
d. Higuchi Model
e. Hixon-Crowell model
f. Korsmeyer- Peppas Model
g. Baker- Lansodale Model
h. Hopfenberg Model
D. RELEASE PROFILE COMPARISION OR
MODEL INDEPENDENT METHOD
a. Ratio test
b. Pair-wise procedures
I. Similarity Factor (f2)
II. Difference Factor (f1)
E. OTHER RELEASE PARAMETER
a. Release time (tx%)
b. Sampling Time
c. Dissolution efficiency (DE)
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
7
8. A. GRAPHICAL METHOD
β’ In this method we plot graph of Time Vs Concentration(Drug) in the OGD or body
fluid simulation dissolution medium or biological fluid
β’ Shape of two curve is compared for comparison of dissolution pattern & the
concentration of drug at each point is compared for extent of dissolution
β’ If two or more curves are overlapping then the dissolution profile is comparable
β’ If difference is small then it is accepted but higher differences indicate that the
dissolution profile is not comparable
β’ m
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
8
A
B
100%
0%
Concentration
Time
A
B
100%
0%
Concentration
Time
A
B
100%
0%
Concentration
Time
A
B
100%
0%
Concentration
Time
1 2 3 4
9. B. STATISTICAL METHOD
β’ This also called statistical analysis, mainly included;
β’ SINGLE TIME POINT DISSOLUTION
I. t-Students' Test
II. ANOVA
β’ MULTIPLE TIME POINT DISSOLUTION
I. MANOVA
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
9
10. STUDENTβS T-TEST
β’ STUDENTβS T-TEST:
β’ This have some tests like,
β’ One sample t-Test
β’ Paired t-Test
β’ Unpaired t-Test
β’ The equation for βtβ is;
π‘ = π β π Γ· π Γ· π
Where,
X = Sample Mean
N = Sample Size
S = Sample Standard Deviation (SSD)
Β΅ = Population Standard Deviation (PSD)
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
10
11. ANOVA
β’ This test is generally applied to different groups of data. Here we compare the variance of
different group of data & predict weather the data are comparable or not.
β’ Minimum three sets of data are required. Here first we have to find the variance within
each individual group and than compare them with each other.
β’ Step to perform ANOVA:
β’ There are five steps,
1. Calculate the total sum of the squares of variance(SST)
πππ = πππ2 β
π2
π
Where, Xij = Shows the Observation
T2/N = Correction Factor (CF)
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
11
12. ANOVA(CONT..)
2. Calculate the variance b/w the samples(SSC)
πππΆ =
πΆπ2
β
β
π2
π
Where, Cj = sum of jth column
h = No of rows
3. Calculate the variance within the samples
πππΈ = πππ β πππΆ
4. Calculate the F-Ratio
πΉπ = πππΆ
π β 1 Γ· πππΈ
π β π
k-1 = Degree of Freedom
5. Compare Fc Calculated with the FT (Tabulated Value)
If Fc<FT, accepted H0.
If H0 is accepted it can be concluded that the difference is not significance and hence could have
arisen due to fluctuation of random sampling.
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
12
13. ANOVA(CONT..)
All the information about the analysis of variance is summarized in the following ANOVA
table:
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
13
Sources of
Variation
Sum of
square (SS)
Degree of
Freedom (d.f.)
Mean Square
(M.S.)
Variance
Ration of F
Variance
Ration of F
SSC k-1 πππΆ
= πππΆ
π β 1
Within the
sample
SSE N-k πππΆ
= πππΈ
π β π
Total SST N-1
MSC = Mean Sum of Square b/w samples
MSE = Mean Sum of Square within samples
14. MANOVA
β’ MANOVA = Multivariate Analysis of Variance
β’ This is generally applied to different groups of date.
β’ Here we compared the variance of different groups of data & predict weather the
data are comparable or Not
β’ Minimum Three sets of data are required. Here first we have to find the variance
within each individual group & then compare with each other
β’ It generally calculated with software after calculating ANOVA by wilkβs Lambda
equation;
β’ Wilkβs Lambda =
E
H+E
β’ E = error some of square and cross production matrix
β’ H = hypothesis sum of square and cross production matrix
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
14
15. C. MATHEMATICAL MODEL
DEPENDANT METHODS
β’ For quantitative interpretation of values
obtained as dissolution assays is easier
to using following mathematical
models/Equations, which describe the
release profile which further relate to all
types dosage forms. Like;
a. ZERO ORDER KINETICS MODEL
b. FIRST ORDER KINETICS MODEL
c. SECOND ORDER KINETICS MODEL
d. WEIBULL MODEL
e. HIGUCHI MODEL
f. HIXON-CROWELL MODEL
g. KORSMEYER- PEPPAS MODEL
h. BAKER- LANSODALE MODEL
i. HOPFENBERG MODEL
j. QUADRATIC MODEL
k. LOGISTIC MODEL
l. GOMPERTZ MODEL
m. HOPFENBERG MODEL
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
15
16. ZERO ORDER KINETICS MODEL
β’ Zero Order API release contributes drug release from dosage for that is independent of amount of
drug in delivery system (i.e. constant drug release)
β’ Drug Release Rate is independent of Concentration
β’ Graphically we will get always of a Straight line within %CDR Vs Time
β’ Equation:
π0 β ππ‘ = πΎπ‘
Where,
W0 = Initial amount of drug in dosage form
Wt = Amount of drug in the dosage form at time βtβ
K = Proportionality t
β’ This Equation can written as,
ππ‘ = π0 + πΎ0 π‘
Where,
Qt = The amount of drug dissolved in time t
Q0 = Initial amount of drug in the solution
K0 = Zero Order Constant (Mostly it is considered as ZERO)
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
16
100%
0%
Cumulative%ofDrug
Release
Time in Hrs.
17. ZERO ORDER KINETICS MODEL
(CONT..)β’ This release is achieved by making;
β’ Reservoir Diffusion System
β’ Osmotically Controlled Devices
β’ EXAMPLES WHERE IT IS APPLIED:
β’ Transdermal DDS
β’ Implantable Depot.
β’ Oral Control Release
β’ Matrix Tablet with low solubility drug
β’ Suspension
β’ Oral osmotic pressure
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
17
18. FIRST ORDER KINETICS MODEL
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
18
β’ Used to describe absorption and/or elimination of some drugs, although it is difficult to
conceptualise this mechanism in a theoretical basis.
β’ The dissolution phenomenon of a solid-particle in a liquid media implies a surface action & seen by
Noyes-Whitney Equation:
ππΆ
ππ‘
= πΎ πΆπ β πΆ
β’ Where,
dC/dt = Dissolution Rate
Cs = Solubility at Max/ Saturation or Concentration of drug at stagnant layer
C = Drug concentration in Bulk of solution in time t
β’ At Sink condition = dissolution rate limiting step for in-vitro study absorption = dissolution rate
limiting step for in-vitro study, so this equation will be,
ππΆ
ππ‘
= πΎ πΆπ = πΆπππ π‘πππ‘
β’ So it becomes , ππ‘ = π0. πβπΎπ‘
Where,
Qt = Drug dissolved in time t
Q0 = Initial drug concentration
K = Constant at time t
19. FIRST ORDER KINETICS MODEL
(CONT..)
β’ USED IN GENERALLY MOSTLY;
β’ Water soluble drugs in porous matrix
β’ Low Water soluble drug in porous matrix
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
19
20. WEIBULL MODEL
β’ This equation can be successfully applied to almost all kinds of dissolution curves
by preceding equation;
log βln(1 β π) = π Γ log(π‘ β π‘π) β log π
Where,
β’ m = cumulated fraction of drug in solution at time t
β’ a = time scale parameter or time scale of process, it can be replaced by more informative
dissolution time (td) or ordinate value in graph, a can be calculated by formula; π = ππ
π
,
Where Td is time necessary to dissolve or release 63.2% of drug from dosage.
β’ Ti = Location parameter or lag time before onset of dissolution or release process & it is
mostly zero
β’ b = shape parameter or slop of line in graph
If b = 0 then Curve as either exponential
If b > 1 then sigmoid shape with upward curvature followed by a turning point
If b < 1 then parabolic with higher initial slop & after that consistent with exponential
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
20
21. WEIBULL MODEL (CONT..)
β’ USED FOR,
β’ Almost all type of dissolution curve
β’ CRITICISM:
β’ There is not any kinetic fundamental and could only describe, but does not adequately
characterize, the dissolution kinetic properties of the drug
β’ There is not any single parameter related with the intrinsic dissolution rate of drug
β’ It is of limited use for establishing in in-vivo/ in-vitro correlation
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
21
22. HIGUCHI MODEL
β’ Higuchi proposed this model in 1961 to describe the drug release from matrix
system
β’ It is assume that these system are neither surface coated nor that their matrices
undergo a significant alteration in the presence of water.
β’ Equation:
ππ‘ = π = π΄ π· 2πΆ β πΆπ πΆπ . π
β’ Where,
β’ Q = Amount of drug release in time t per unit area A
β’ C = Initial drug Concentration
β’ Cs = Drug solubility in Matrix media
β’ D = Diffusivity of the drug molecules
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
22
23. HIGUCHI MODEL (CONT..)
β’ IT IS DEVELOPED TO STUDY THE RELEASE OF
β’ Diffusion Matrix system:
β’ Homogenous matrices of Suspension from ointment base
β’ Planar or spherical system having a granular heterogenous matrix
β’ Water soluble drugs incorporated in semi-solid or solid matrix
β’ Low water soluble drug incorporated in semi-solid or solid matrix
β’ Too accordance with other all types dissolution from other pharmaceutical dosage forms
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
23
24. HIXON-CROWELL MODEL
β’ To evaluate the drug release with change in the surface area and the diameter of
the particles/ tablets
β’ The rate of dissolution depends on the surface of solvent
so THE LARGE IS AREA THE FASTER IS DISSOLUTION.
β’ Both scientist recognized that Particle regular area is proportional to the cubic root
of its volume, so describe a equation for easier,
π0
1
3 β π
1
3 = πΎ Γ π‘
Where,
M0 =Original mass of API Particles
K = Cubic root dissolution rate constant
M = Mass of the API at the time βtβ
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
24
25. HIXON-CROWELL MODEL (CONT..)
β’ APPLICABLE FOR
β’ Polymeric matrix system
β’ Erodible Matrix Formulations
Note: when this model is, it is assumed that the release rate is limited by the drug
particles dissolution rate and not by the diffusion that might occur through the
polymeric matrix.
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
25
26. BAKER- LANSODALE MODEL
β’ In 1974 Baker- Lonsdale developed the model from Higuchi model and given
equation;
3
2
1 β 1 β
ππ‘
πβ
2
3
β
ππ‘
πβ
=
3. π· π. πΆ ππ
π0
2. πΆ0
t
Where,
β’ Mt = Drug Release at time t
β’ Mβ = Drug Release at infinite time
β’ Dm = Diffusion coefficient
β’ Cms = Drug solubility in matrix
β’ R0 = Radius of spherical matrix
β’ C0 = Initial concentration at matrix
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
26
27. BAKER- LANSODALE MODEL
(CONT..)
β’ THIS EQUATION HAS BEEN USED TO
β’ Linearization of release data of Microcapsules
β’ Linearization of release data of Microspheres
β’ Matrix system formulations
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
27
28. HOPFENBERG MODEL
β’ Model explain rate limiting step of drug release is erosion of matrix itself
β’ Time dependant diffusional resistance internal or external to eroding matrix do not
influence it. Or simply called as Modified Las time, it calculated by following
equation,
ππ‘
πβ
= 1 β 1 β
πΎ0 π‘
πΆ0 π0
π
Where,
β’ Mt = Drug dissolved in time t
β’ Mβ = Drug dissolved in infinite time
β’ Mm /Mβ = Fraction of drug dissolved
β’ a0 = Initial Radius of sphere or cylinder or half thickness for a slab
β’ C0 = Initial concentration at matrix
β’ n = 1, 2, 3 for a slab, cylinder, and sphere respectively
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
28
29. HOPFENBERG MODEL (CONT..)
β’ CALCULATION OF DRUG RELEASE FROM SURFACE ERODING DEVICE WITH
DIFFERENT GEOMETRIC, LIKE
β’ Slab
β’ Sphere
β’ Infinite cylinder display heterogenous erosion
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
29
30. KORSMEYER- PEPPAS MODEL
β’ The simple relationship which describe the drug release from the polymeric system
equation was derived by Korsmeyer et. al. in 1983
β’ It is used to describe the first 60% release of drug from dosage form
β’ Equation:
ππ‘
πβ
= ππ‘ π
+ π
β’ Where,
β’ Mt/Mβ = Fraction of drug release at time βtβ
β’ a = constant incorporating structure or geometrical characteristics of drug dosage form
β’ n = Release Exponent
β’ n value is used to characterize the drug release for cylindrical matrices and the n
value characterize the release mechanism of drug as described.
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
30
31. KORSMEYER- PEPPAS MODEL
(CONT..)
β’ n value is used to characterize the drug release for cylindrical matrices and the n
value characterize the release mechanism of drug as described;
β’ n is estimated as linear regression of Log (mt/m) Vs Log T
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
31
100%
0%
Log%ofdrugrelease
Log time in Hrs.
Release exponents(n) Indications or drug
transport mechanism
Rate as a function of
time
Less than 0.45 (<0.45) Quasi fickian -
0.45 Fickian Diffusion T-0.5
0.45 < n < 0.89 Non Fickian diffusion tn-1
0.89 to 1 Zero Order Non fickian case 2 Zero order release
More than 1 (>1) Non Fickian super case
2
tn-1
32. KORSMEYER- PEPPAS MODEL
(CONT..)
β’ USED IN;
β’ Could be predicted the best model for the release of drug from the dosage form
β’ Different Pharmaceutical Modified release dosage forms
β’ Polymeric system formulations
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
32
33. D. RELEASE PROFILE COMPARISION
OR MODEL INDEPENDENT
METHODβ’ Model independent Method can be further differentiated to
β’ RATIO TEST
β’ Ratio of Area Under the Curve (AUC)
β’ Mean Dissolution Time(MDT)
β’ PAIR-WISE PROCEDURES
β’ F1 = Difference Factor
β’ f2 = Similarity Factor
β’ ΞΎ1 = Rescigno index or bioequivalence index
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
33
34. RATIO TEST
β’ Parameters from release assay of reference & test at same point(Tx%).
β’ Taken Ratio of AUC of both reference & Test Product
Or
β’ Ratio of Mean Dissolution Time (MDT)
ππ·π =
π=1
π
βππ π‘π
π=1
π
βππ
Where,
j = sample No
n = No. of sample time
tj = Midpoint b/w tj & T(j-1)
βMj = Drug dissolved
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
34
35. PAIR WISE PROCEDURE
β’ Pair wise procedure includes
β’ F1 VALUE: DIFFERENCE FACTOR
β’ F2 VALUE: SIMILARITY FACTOR
β’ RESCIGNO INDEX OR BIOEQUIVALENCE INDEX (ΞΎ1 & ΞΎ2 )
β’ These F1 & F2 equations described by Moore & Flamner and ΞΎ1 & ΞΎ2 by Rescigno.
β’ Both F1 & F2 equations are endorsed by FDA as acceptable method for dissolution
profile comparison
β’ They are used to study the comparison of dissolution profiles of the two dosage
forms.
β’ It can be calculated using Excel or various readymade software (E.g.:
PhEq_bootstrap) and Rescigno index too calculated by Software.
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
35
36. DIFFERENCE FACTOR (F1)
β’ It calculate % difference b/w two curves at each time point & measure relative error b/w two
curves.
β’ F1 equation is sum of absolute values of vertical distance b/w reference (Rt) & Test (Tt) mean
% release values i.e. (Rt-Tt) at each dissolution points.
β’ The f1- Value is equal to zero to zero when the test and reference profiles are identical &
increase as the profile
β’ Equation
π1 =
π‘=1
π
π π‘ β ππ‘
π‘=1
π
π π‘
Γ 100
Where,
Rt = Reference Dissolution Value
n = No of dissolution time points
Tt = Test dissolution value
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
36
37. SIMILARITY FACTOR (F2)
β’ f2 equation is logarithmic transformation of average squared vertical distance b/w
reference & test mean dissolution values at each time point, multiplied by an
approximate weighting i.e. Wt(Rt-Tt).
β’ Equation:
π2 = 50log10 1 +
1
π
π‘=1
π
ππ‘(π π‘ β ππ‘)2
β0.5
Γ 100
Where,
Rt = Reference Dissolution Value
n = No of dissolution time points
Tt = Test dissolution value
Wt = Optional weighting Factor
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
37
38. WHEN ARE DISSOLUTION PROFILE SIMILAR..??
β’ If in both Test & Reference product shows dissolution more than or equal to 85% (β₯
85%) within 15min, then
β’ Profiles are considered to be similar
β’ No further calculations required
β’ F1 value limit : 0% to 15%
β’ F2 Value limit : β₯ 50%
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
38
39. ADDITIONAL REQUIREMENTS FOR F1 & F2
β’ At least 12 unit should used
β’ Same test conditions should maintained
β’ Dissolution time points for Immediate Release(IR) products like 5, 15,30, 60 min
β’ For Sustained Release(SR) Products, 1, 2, 3, 5, 8 Hrs. etc. until at least 85% of drug is
released
β’ Only one measurement should considered after 85% dissolution of drug
β’ Standard Deviation (DV):
β’ β€20% at early time points
β’ β€10% at later time points
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
39
40. EXAMPLE FOR F1 & F2
Time Rt Tt (Rt-Tt) (Rt-Tt)2
10 45 55 10 100
15 65 75 10 100
20 80 90 10 100
30 90 100 10 100
π π‘ = 280 π π‘ β ππ‘ = 40 (π π‘ β ππ‘)2
= 400
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
40
By putting Data in Eq. we will get;
F1 =14
F2 =50
Insert No of points where both products β₯85%
Rt = Cumulative % dissolved of reference product at time t
Tt = Cumulative % dissolved of test product at time t
41. RESCIGNO INDEX
β’ Also called as bioequivalence Index generally used in CR formulations
β’ Used to measure dissimilarity b/w Reference & Test product based on PDC & time
β’ Equation;
ΞΎπ = 0
β
π π π‘ β π π(π‘) π ππ‘
0
β
π π π‘ + π π(π‘) π ππ‘
1
π
Where,
dR t = Reference Product Dissolved amount
dΟ(t) = Test product dissolved at each sample time points
β’ This Rescigno index always lies b/w 0 & 1 (0< ΞΎπ<1)
β’ If ΞΎπ = 0 then Two profiles are similar
β’ If ΞΎπ = 1 then either test or reference not release at all
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
41
42. E. OTHER RELEASE PARAMETER
I. RELEASE TIME (tX%) :
β’ Time Necessary to release determine % of Drug
E.g.: 20% of drug in pre-planned time
II. SAMPLING TIME (AX%):
β’ The amount of drug w.r.t. time tx%
E.g.: X amount of drug released in 20min
III. DISSOLUTION EFFICIENCY (DE):
β’ The area under the dissolution curve upto a certain time t, expressed as % of area of
rectangle describe the 100% dissolution in the same time.
π·πΈ % =
ππ΄
π
Γ 100 β π·πΈ % = 0
π‘
π. ππ‘
π100. π‘
Γ 100
Where,
β’ SA = Shaded Area
β’ R= Rectangle Area
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
42
43. SUMMARY
S. No. Model Name Graph to be Estimated Equation Application for
1 Zero Order Kinetic Model Cumulative Release Vs Time ππ‘ = π0 + πΎ0 π‘ TDDS, Coating, Osmotic System
2 First Order Kinetic Model Log Cumulative Release Vs Time ππ‘ = π0. πβπΎπ‘ Water soluble & Low soluble drugs in
porous matrix
3 Second Order Kinetic Model Release amount Fraction to infinite time
Vs real time
ππ‘
πβ
= πβ β ππ‘ . πΎ2 π‘
NA
4 Weibull Model Log Cumulative Release Vs Log Time log βln(1 β π)
= π Γ log(π‘ β π‘π) β log π
Almost all type of dissolution curves
5 Higuchi Model % Cumulative Relase Vs (Time)1/2
ππ‘ = π = π΄ π· 2πΆ β πΆπ πΆπ . π Diffusion Matrix formulation
6 Hixon β Crowell Model %CRt/CRβ Vs (Time)1/2
π0
1
3 β π
1
3 = πΎ Γ π‘ Erodible matrix formulation
7 Korsmeyer β Peppas model (Unreleased fraction)1/3 Vs Time ππ‘
πβ
= ππ‘ π
+ π
MR Dosage forms
8 Baker β Lonsdale Model Mt/Mβ Vs Time
3
2
1 β 1 β
ππ‘
πβ
2
3
β
ππ‘
πβ
=
3. π· π. πΆ ππ
π0
2. πΆ0
t
Microsphere, Microcapsules
9 Hopfenberg Mt/Mβ Vs Erosion Time ππ‘
πβ
= 1 β 1 β
πΎ0 π‘
πΆ0 π0
π Erosion matrix itself
10 Gompertz %dissolved Vs Max dissolution w.r.t. time ππ‘ = π΄. πβπβπΎ(π‘βπ) Comparing b/w good & intermediate
release
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
43
44. REFERENCE
β’ Brahmankar D.M., Jaiswal S. B., 2013. Biopharmaceutics & Pharmacokinetics a
treatise, Vallabh Prakashan 32 ISBN 978-81-85731-47-6
β’ Costa P., Lobo J.M.S., 2000. Modelling & Comparison of dissolution profiles, EJPS 12
(2001) 123-133
26-09-2019Mahendra Pratap Swain, PHDPD100102019, BIT-MESRA, RANCHI
44